Ranibizumab Versus Dexamethasone Implant in Diabetic Macular Edema

Macular Thickness and Vessel Density Changes After Dexamethasone Implant and Ranibizumab Intravitreal Injection in Diabetic Macular Edema: 6-month Follow-up

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03385382

Acronym

LED

Enrollment

Registered

2017-12-28

Start date

2016-12-06

Completion date

2017-06-27

Last updated

2018-01-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic Macular Edema

Brief summary

Between December 2016 and June 2017 a total of 40 eyes from 40 diabetic retinopathy patients with diabetic macular edema were recruited at the Ophthalmologic Clinic of University G. d'Annunzio, Chieti-Pescara, Italy.

Interventions

DRUGDexamethasone intravitreal implant 0.7 mg

Intravitreal Implant of dexamethasone

DRUGRanibizumab Injection

Injection of ranibizumab

Study design

Observational model

OTHER

Time perspective

OTHER

Eligibility

Sex/Gender

ALL

Age

19 Years to 90 Years

Healthy volunteers

Inclusion criteria

* Age \>18 years old * BCVA greater than 0.5 LogMAR in the study eye at baseline examination * Presence of recent DME * CMT \> 300µm as measured using the SD-OCT at the baseline examination

Exclusion criteria

* Any previous ocular surgery in the last 6 months * Laser treatments * Prior ocular trauma * Retinal vascular diseases * Vitreo-retinal interface diseases * Medium lens opacities (according to Lens Opacities Classification System)

Design outcomes

Primary

Measure	Time frame	Description
Central macular thickness	6 months	Decrease of macular thickness

Secondary

Measure	Time frame	Description
visual acuity	6 months	Increase of mean visual acuity

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026